MicroPort CRM Receives Approval in Japan for Alizea Bluetooth Pacemaker.
CLAMART, France, Jan. 17, 2022- MicroPort CRM, a pioneer in the field of Cardiac Rhythm Management with headquarters in France, recently got permission from the PMDA, a Japanese regulatory organization, for its Alizea implantable pacemaker line. When linked with MicroPort CRM’s SmartView Connect home monitor, which is already certified in Japan, the devices are outfitted with Bluetooth technology for seamless remote monitoring.
Cardiologists can remotely monitor devices using Alizea pacemakers. The SmartView Connect home monitor is designed to be placed at the patient’s bedside to allow for the regular transmission of detailed reports to the cardiologist on the pacing system’s operation, eliminating the need for patients to visit the hospital for simple routine examinations and thus reducing the healthcare system’s burden. When patients present symptoms, Alizea pacemakers, and the SmartView Connect home monitor work together to provide the cardiologist with timely alerts and transmissions, allowing for faster and more effective patient care.
Noboru Shimizu, VP of MicroPort CRM Sales Japan, commented, “Around 64,000 patients are implanted with a pacemaker each year in Japan, and coupled with the difficulties that have arisen from the current health crisis, there is a growing need to monitor patients remotely, without them having to travel. Thanks to Alizea pacemakers and its SmartView Connect monitor, we are positioning ourselves in the Japanese market with the very best in cardiac pacing. I am convinced that this will allow us to strengthen our presence in Japan.”
Benoît Clinchamps, President of MicroPort CRM, noted, “We successfully launched Alizea in Europe in June 2021, and Japan is the second region to benefit from its advanced technological functions. As part of our commitment to improve the lives of as many patients as possible, and to support healthcare professionals in their mission, we will continue to deploy Alizea and Smartview Connect around the world.”
MicroPort CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, near Paris, France. Through its long-standing expertise in CRM, MicroPor CRM develops, manufactures, and markets cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems, and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure, globally.
For more information, please refer to www.microport.com